NCT04681768: Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symptomatic Visceral Metastases or High Tumor Burden

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patients without prior first line therapy (endocrine or chemotherapy) for metastatic breast cancer; Patients who received any CDK4/6 inhibitor (e.g. Ibrance/palbociclib, abemaciclib/Verzenio, ribociclib/Kisqali); Patients with bone-only disease

Comments are closed.

Up ↑